49 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
to similarly situated executives with the first such review effective January 2025.
(b)Annual Bonus. Subject to the terms of the Executive Severance … a bonus following the end of each calendar year that ends during the Employment Period (“Annual Bonus”), subject to: (i) objective criteria set forth
8-K
tqwe9efgxo1ap j8c
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-10.1
7rt9mv nz
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
424B3
ud8qw
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
blodnlen3gn36x7n 22
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
S-4
mdv70ab4 rsji7
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm
8-K
o116j9
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
EX-10.1
142jzuel
4 May 22
Adaptimmune Announces Appointment of Joanna Brewer as Chief Scientific Officer
8:20am
8-K
aphzz ooh8mtjad1xs
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am
8-K
EX-10.01
0u7z0y8yj 06rm238
26 Jan 22
Adaptimmune Announces Appointment of Cintia Piccina as Chief Commercial Officer
8:05am